1. Show article details.

    Emergent signs 5-yr deal backing J&J COVID-19 vaccine

    Reuters – 7:39 AM ET 07/06/2020

    Emergent BioSolutions Inc (EBS) said on Monday it signed a five-year contract to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, adding to a series of deals likely to put it at the heart of future global vaccine production.

  2. Show article details.

    BRIEF-Vaxart’S Covid-19 Vaccine Selected For The U.S. Government’S Operation Warp Speed

    Reuters – 8:58 AM ET 06/26/2020

    Vaxart Inc (VXRT): * VAXART’S COVID-19 VACCINE SELECTED FOR THE U.S. GOVERNMENT’S OPERATION WARP SPEED. * VAXART (VXRT) - CO'S ORAL COVID-19 VACCINE SELECTED TO PARTICIPATE IN A NON-HUMAN PRIMATE CHALLENGE STUDY ORGANIZED & FUNDED BY OPERATION WARP SPEED Source text for Eikon: Further company coverage:

  3. Show article details.

    Vaxart says potential COVID-19 vaccine picked for 'Operation Warp Speed'

    Reuters – 8:15 AM ET 06/26/2020

    Vaxart Inc (VXRT) said on Friday it would test its potential COVID-19 vaccine on animals under the U.S. program titled "Operation Warp Speed", which is meant to speed up the development of COVID-19 therapeutics and vaccines. Shares of the U.S. drug developer jumped 63% before the opening bell.

  4. Show article details.

    Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed

    GlobeNewswire – 8:00 AM ET 06/26/2020

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for ...

  5. Show article details.

    BRIEF-Vaxart Signs Memorandum Of Understanding With Attwill Medical Solutions Sterilflow,

    Reuters – 8:37 AM ET 06/25/2020

    Vaxart Inc (VXRT): * VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH ATTWILL MEDICAL SOLUTIONS STERILFLOW, LP. * Vaxart Inc (VXRT) - ENABLING PRODUCTION OF A BILLION OR MORE COVID-19 VACCINE DOSES PER YEAR. * Vaxart Inc (VXRT) - AMS WILL BE ASSIGNING DEDICATED RESOURCES AND EQUIPMENT FOR SCALE UP AND COMMERCIAL PRODUCTION OF VACCINE Source text for Eikon: Further company coverage:

  6. Show article details.

    Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP

    GlobeNewswire – 8:00 AM ET 06/25/2020

    Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year Through Large Scale Lyophilization, Tableting and Coating Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that it signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP affirming the parties’...

  7. Show article details.

    BRIEF-Vaxart Inc Set To Join Russell 3000 Index

    Reuters – 8:13 AM ET 06/24/2020

    Vaxart Inc (VXRT): * VAXART, INC. SET TO JOIN RUSSELL 3000® INDEX Source text for Eikon: Further company coverage:

  8. Show article details.

    Vaxart, Inc. Set to Join Russell 3000® Index

    GlobeNewswire – 8:00 AM ET 06/24/2020

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell 3000Ò Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective Monday, June 29th 2020 after the U.S. market opening.

  9. Show article details.

    BRIEF-Vaxart - Received Letter From Nasdaq Noting That Co Was Not In Compliance With Requirement Of Certain Listing Rule

    Reuters – 5:05 PM ET 06/23/2020

    Vaxart Inc (VXRT): * VAXART (VXRT) - ON JUNE 22, RECEIVED LETTER FROM NASDAQ NOTING THAT CO WAS NOT IN COMPLIANCE WITH REQUIREMENT OF CERTAIN LISTING RULE Source text for Eikon: https://bit.ly/3dumG5l Further company coverage:

  10. Show article details.

    Hand Sanitizers Offer Peace of Mind in an Increasingly Connected World

    PR Newswire – 9:00 AM ET 06/23/2020

    NEW YORK, June 23, 2020 Under current conditions, many companies in various industries have had to find a niche from which to benefit. While biotech companies report work on vaccines and possible treatments and medical device companies progress on patient monitoring, many others have been working on improving testing options.

  11. Show article details.

    Vaxart, Inc. to Present at the H.C. Wainwright Virtual Fireside Chat Series

    GlobeNewswire – 8:00 AM ET 06/23/2020

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that Andrei Floroiu, Chief Executive Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:25 am ET A live audio webcast of the presentation will be accessible on the Events page of...

  12. Show article details.

    BRIEF-Vaxart Appoints New CEO To Accelerate Advancement Of COVID-19 And Other Programs

    Reuters – 8:17 AM ET 06/15/2020

    Vaxart Inc (VXRT): * VAXART, INC. APPOINTS NEW CEO TO ACCELERATE ADVANCEMENT OF COVID-19 AND OTHER PROGRAMS. * Vaxart Inc (VXRT) - ANDREI FLOROIU APPOINTED CHIEF EXECUTIVE OFFICER. * Vaxart Inc (VXRT) - WOUTER LATOUR, MD, TO CONTINUE AS CHAIRMAN OF BOARD Source text for Eikon: Further company coverage:

  13. Show article details.

    Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs

    GlobeNewswire – 7:30 AM ET 06/15/2020

    Andrei Floroiu Appointed Chief Executive OfficerWouter Latour, MD, to Continue as Chairman of the Board Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that effective today it has appointed Andrei Floroiu as Chief Executive Officer.

  14. Show article details.

    BRIEF-Armistice Capital Reports 19.99% Stake In Vaxart As Of June 2 - SEC Filing

    Reuters – 6:17 PM ET 06/09/2020

    Vaxart Inc (VXRT): * ARMISTICE CAPITAL LLC REPORTS 19.99% STAKE IN VAXART INC AS OF JUNE 2 - SEC FILING. * ARMISTICE CAPITAL LLC - HAD PREVIOUSLY REPORTED 11.3% STAKE IN VAXART INC AS OF MAY 20 Source : Further company coverage:

  15. Show article details.

    Vaxart to Present at the Jefferies Virtual Healthcare Conference

    GlobeNewswire – 8:00 AM ET 06/03/2020

    Vaxart (VXRT), Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that Wouter Latour, MD, chief executive officer of Vaxart (VXRT) is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:00 p.m. Eastern Time.

  16. Show article details.

    U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine

    Reuters – 7:50 AM ET 06/01/2020

    The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions (EBS) to boost manufacturing capacity for a potential COVID-19 vaccine. As drugmakers race to develop vaccines, tests and therapies for COVID-19, the United States is looking to secure manufacturing capacity under its "Operation Warp Speed" program announced in May to accelerate vaccine development.

  17. Show article details.

    BRIEF-Kindred Biosciences Reports Covid-19 Vaccine Manufacturing Agreement With Vaxart

    Reuters – 8:00 AM ET 05/20/2020

    Kindred Biosciences Inc (KIN): * KINDRED BIOSCIENCES ANNOUNCES COVID-19 VACCINE MANUFACTURING AGREEMENT WITH VAXART. * Kindred Biosciences Inc (KIN) - KINDREDBIO WILL MANUFACTURE VACCINE FOR CLINICAL TRIALS BEGINNING IN SECOND HALF OF 2020. * KINDRED BIOSCIENCES (KIN) - WILL PRODUCE CANDIDATE VACCINE BULK DRUG SUBSTANCE UNDER GOOD MANUFACTURING PRACTICES.

  18. Show article details.

    Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate

    GlobeNewswire – 8:00 AM ET 05/20/2020

    KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine unde...

  19. Show article details.

    Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart

    PR Newswire – 7:58 AM ET 05/20/2020

    SAN FRANCISCO, May 20, 2020 Kindred Biosciences, Inc. (KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (VXRT) for the manufacture of Vaxart's (VXRT) oral vaccine candidate for COVID-19. "We are proud to be contributing toward the effort to develop a COVID-19 vaccine.

  20. Show article details.

    BRIEF-Armistice Capital Reports 14% Stake In Vaxart As Of May 11

    Reuters – 6:16 PM ET 05/18/2020

    Vaxart Inc (VXRT): * ARMISTICE CAPITAL, LLC REPORTS 14.0 % STAKE IN VAXART AS OF MAY 11, 2020 - SEC FILING. * ARMISTICE CAPITAL, LLC HAD PREVIOUSLY REPORTED 22.5% STAKE IN VAXART AS OF APRIL 28, 2020 Source text: Further company coverage:

Page:

Today's and Upcoming Events

  • Aug
    24

    VXRT to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    12

    VXRT announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.